PRMT1 has been demonstrated to promote the EMT program of breast cancer cells by activating ZEB1 [158] and to confer resistance to cetuximab in TNBC cell lines [159], and its overexpression was correlated with cancer malignancy and poor prognosis by methylating and inactivating C/EBPα [160]. The gene discussed is ZEB1; the disease is breast carcinoma.